Skip to main content

BD Sees Q3 Sales Hop 10 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson said today that its revenues swelled 10 percent in its fiscal third quarter, with growth coming from across all its divisions.

BD had total revenues of $2.01 billion for the three-month period ended June 30, compared to $1.83 billion for the third quarter of 2010.

Sales for the BD Medical segment rose around 10 percent to $1.04 billion from $945.5 million year over year; sales for the BD Diagnostics segment were up nearly 10 percent to $631.4 million from $576.3 million; and sales for the BD Biosciences business increased 9 percent to $337.9 million from $309.1 million, with the majority of its Biosciences growth being driven by international sales.

The firm's net income for the quarter was $343.1 million, or $1.53 per share, up 12 percent compared to net income of $306.9 million, or $1.29 per share, for the third quarter of 2010. That performance beat analysts' average expected earnings of $1.43 per share on estimated revenues of $1.99 billion.

BD's spending on research and development increased 7 percent to $115.7 million from $108 million in the year-ago period, and its SG&A expenses were up 14 percent at $474.6 million versus $416.5 million from a year ago.

The Franklin Lakes, NJ-based company said it expects revenue growth for the full fiscal year to be at the high end of 5 percent to 6 percent compared to 2010, due to the effects of favorable currency.

The firm also is raising its full-year 2011 guidance for EPS to a range of $5.65 to $5.70, which would represent an increase of between 15 and 16 percent from a year ago. The company had earlier given guidance of $5.55 to $5.65.

“We are pleased with our solid results this quarter, with all three segments contributing to growth,” said company Chairman and CEO Edward Ludwig, in a statement. “Gross margin expansion reflecting favorable product mix has offset some of the headwinds we have been facing as a result of a challenging macroeconomic environment and increased raw material costs.”

In early morning trading on the New York Stock Exchange, shares of BD were down more than 1 percent to $81.20.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.